Metraipolis › archive › dc_88f5adfa2cc4
Quantitative benefit-risk analysis for prophylactic vaccines in the context of FDAs benefit-risk framework — Europe PMC PMID:41644572
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41644572
- DOI
- 10.1038/s41541-[numero omesso]-3
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T02:34:53.738Z
- SHA-256 of the archived text
6d7637650e909ca0d8a06847c2c02baa043b83ba37139b974e416d1d92422eaa- Stable URL of this page
https://metraipolis.com/documento/dc_88f5adfa2cc4
How to cite
Quantitative benefit-risk analysis for prophylactic vaccines in the context of FDAs benefit-risk framework — Europe PMC PMID:41644572 — Europe PMC (en), https://europepmc.org/article/MED/41644572 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_88f5adfa2cc4 (Metraipolis archive dc_88f5adfa2cc4, sha256 6d7637650e909ca0d8a06847c2c02baa043b83ba37139b974e416d1d92422eaa)
BibTeX
@misc{dc88f5adfa2cc4,
title = {Quantitative benefit-risk analysis for prophylactic vaccines in the context of FDAs benefit-risk framework — Europe PMC PMID:41644572},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41644572},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_88f5adfa2cc4; sha256 6d7637650e909ca0d8a06847c2c02baa043b83ba37139b974e416d1d92422eaa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41644572. Agents can read the archived copy with the MCP tool read_document.